Preparation method of decoquinate nano powder, product and application of decoquinate nano powder

Decoxyquine nanopowder was prepared through ultrafine crushing and adjuvant treatment, which solved the problem of low bioavailability and achieved high-efficiency and low-dose therapeutic effect, and was suitable for the treatment and prevention of livestock and poultry parasites.

CN119015233AInactive Publication Date: 2024-11-26SHANDONG DEZHOU SHENNIU ANIMAL HEALTH PROD CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411163268.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

As a difficult-to-soluble drug, decioxquine has problems with low bioavailability and high metabolic rate, resulting in oral malabsorption. The preparation method and application of its nano powder are lacking in the prior art.

Method used

Decoxyquine nano powder is prepared by ultrafine pulverizing, adding stabilizers, solubilizers, surfactants, emulsifiers, dispersants and other adjuvants for grinding, shearing and emulsification, and spray-drying it to prepare decoxyquine nano powder to make its particle size meet the nano standard , restores nanoparticle size, and facilitates water dissolving use.

Benefits of technology

It improves the bioavailability of decioxquine, reduces the dosage, reduces drug resistance and drug residues, improves the safety and quality of livestock products, and achieves more efficient therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005007067300000061
    Figure BDA0005007067300000061
  • Figure BDA0005007067300000071
    Figure BDA0005007067300000071
  • Figure BDA0005007067300000072
    Figure BDA0005007067300000072
Patent Text Reader

Abstract

The invention discloses a preparation method of decoquinate nano-powder, a product and application of the decoquinate nano-powder, and belongs to the technical field of veterinary chemical medicines. The preparation method comprises the following specific steps: (1) carrying out superfine grinding on decoquinate; (2) adding HPMC, Tween 80, lauryl sodium sulfate, dimethyl silicone oil and poloxamer into purified water to obtain a solution A; (3) adding HPMC and maltodextrin into purified water to obtain a solution B; (4) adding decoquinate into the solution A, and grinding to obtain a suspension C; (5) adding the suspension C into the solution B to obtain a decoquinate nano suspension D; and (6) spray drying is performed to obtain decoquinate nano powder, the decoquinate nano powder is dissolved in water according to the mass ratio of 1: 50, and the particle size of decoquinate can reach the particle size of decoquinate in the decoquinate nano suspension. The decoquinate nano powder disclosed by the invention is small in particle size, suspended in water, convenient to use, high in bioavailability, small in dosage and high in cost performance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of veterinary chemical medicines, and more particularly to a preparation method and product of decoquinate nano powder and application thereof. Background Art

[0002] Decoquinate is a quinoline derivative and a highly effective anticoccidial drug for livestock and poultry. It has been registered and used in many countries around the world. In addition to being used for coccidia, decoquinate also has varying degrees of control effects on parasites such as Plasmodium (avian leukocytozoonosis), Toxoplasma, Cryptosporidium and Sarcocystis. In my country, there are three types of decoquinate preparations: 6% decoquinate premix, decoquinate solution (3%, 2.25%) and decoquinate dry suspension.

[0003] In the Biopharmaceutical Classification System (BCS), decoquinate is classified as a Class II active pharmaceutical ingredient, which means that the drug has low water solubility and high permeability through the intestinal membrane. In addition, due to its low solubility and high metabolic rate, it is also classified as a Class II drug in the Biopharmaceutical Drug Disposition Classification System (BDDCS). Due to these unfavorable properties, these drugs may have serious oral absorption problems, which may lead to reduced bioavailability.

[0004] As a poorly soluble drug, decoquinate is developed and utilized by reducing the particle size through nanotechnology, improving solubility and dissolution, thereby increasing bioavailability, thereby achieving drinking water administration and reducing the dosage. However, in the prior art, no special reports or patents on the preparation method of decoquinate nanopowder and its application have been found.

[0005] Therefore, providing a method for preparing decoquinate nanopowder is an urgent problem to be solved by those skilled in the art. Summary of the invention

[0006] In order to facilitate use, administer the drug by drinking water, maximize the bioavailability of the drug, improve the efficacy, reduce the dosage, reduce drug resistance, reduce drug residues, improve the safety and quality of livestock products, and better serve the animal husbandry industry, the present invention discloses a preparation method and product of decoquinate nano powder and its application. The present invention processes decoquinate by ultrafine grinding, adding adjuvants such as stabilizers, solubilizers, surfactants, emulsifiers, and dispersants, grinding, shearing, emulsification, and other nano-series processes, and spray drying is performed after the particle size of decoquinate reaches the nanometer standard. When dissolved in water for use, the nanometer particle size can be restored.

[0007] One of the purposes of the present invention is to provide a method for preparing decoquinate nanopowder, comprising the following steps:

[0008] (1) Weigh a certain amount of decoquinate and add it to an ultrafine grinder to obtain D50 5~15μm, D 90 20-40 μm decoquinate;

[0009] (2) Weigh a certain amount of HPMC, Tween 80, sodium lauryl sulfate, dimethyl silicone oil, and poloxamer, add them to purified water to obtain a clear and transparent solution A for later use;

[0010] (3) Weigh a certain amount of HPMC and maltodextrin, add them to purified water to obtain a clear and transparent solution B for later use;

[0011] (4) Add decoquinate to solution A and grind thoroughly to obtain a particle size D 50 100~300nm, D 90 400-600nm suspension C;

[0012] (5) Suspension C is added to solution B, sheared and stirred, and the particle size D of decoquinate is detected. 50 100~300nm, D 90 400-600 nm, to obtain decoquinate nanosuspension D;

[0013] (6) The decoquinate nanosuspension D was spray dried, powdered, and passed through a 300-mesh sieve to obtain decoquinate nanopowder.

[0014] Preferably, the mass ratio of the decoquinate in step (1) to the HPMC, Tween 80, sodium lauryl sulfate, dimethicone, poloxamer and purified water in step (2) is (20-40):(0.2-0.4):(10-20):(0.20-0.40):(1.5-2.5):(2-4):100.

[0015] The beneficial effects of adopting the above technical solution are as follows: the above raw material combination and ratio are an organic combination of surfactants, stabilizers and defoamers, so that the particle size of the decoquinate nanosuspension is more uniform and the production efficiency is higher during the preparation process, which is the material basis for successfully restoring the nanoparticle size after dissolving in water after powdering.

[0016] Preferably, the mass ratio of the decoquinate in step (1) to the HPMC, maltodextrin and purified water in step (3) is (20-40):(0.5-1):(40-60):100.

[0017] The beneficial effects of adopting the above technical solution are: the above raw material combination and proportion are stable carriers of decoquinate nanoparticles, which are necessary conditions for improving the spray drying powder production yield and production efficiency of decoquinate nanosuspension.

[0018] The beneficial effects of solution A and solution B on nano products are as follows: solution A is a stabilizing system of surfactants, dispersants and defoamers, and solution B is a carrier of decoquinate, which ensure that the decoquinate nano powder is smoothly made into a nano suspension during the preparation process and the nano particle size is successfully restored after the spray powder is dissolved in water.

[0019] Preferably, the grinding equipment in step (4) is selected from a colloid mill, a high-pressure homogenizer, and a sand mill, and the grinding is performed for 2 to 4 hours.

[0020] Preferably, the shearing and stirring in step (5) is performed at a speed of 2900 r / min for 40 to 60 min.

[0021] The beneficial effects of adopting the above technical solution are: grinding is the way to reduce the particle size of decoquinate to nanometers, and shearing and stirring make the decoquinate nanosuspension more evenly mixed and dispersed.

[0022] Preferably, the spray drying in step (6) sets the inlet air temperature to 100-130°C (preferably 110-120°C), the outlet air temperature to 60-90°C (preferably 70-80°C), the steam pressure to 0.05-0.10MPa, the nozzle pressure to 0.03-0.05MPa, and the pressure tank temperature to 70-90°C.

[0023] The beneficial effect of the above-mentioned spray drying on the nano-product is that it makes it possible to evenly suspend decoquinate in water, thus solving the problem that decoquinate is insoluble in water.

[0024] The second object of the present invention is to provide a decoquinate nano powder, which is soluble in water at a mass ratio of 1:50, and the particle size D of decoquinate in the decoquinate nano powder is 50 100~300nm, D 90 400~600nm.

[0025] The technical concept of the present invention is as follows: the present invention prepares decoquinate into a decoquinate nanosuspension, which is then spray-dried to form a powder, and the particle size before powder spraying is reached after being dissolved in water, thereby solving the problem that the nanoformulation is difficult to recover due to reaggregation, and at the same time improving the bioavailability and therapeutic effect of decoquinate, making it convenient to use.

[0026] The third object of the present invention is to provide an application of decoquinate nanopowder for the treatment and prevention of parasites such as coccidiosis, malarial parasites, toxoplasma, cryptosporidium, and sarcocystis in livestock and poultry.

[0027] The decoquinate nano powder of the present invention maximizes the bioavailability of the drug, improves the therapeutic effect, reduces the dosage, reduces drug resistance, reduces toxic and side effects, reduces drug residues, improves the safety quality of livestock products, and has significant economic and social benefits.

[0028] It can be seen from the above technical solution that, compared with the prior art, the beneficial effects of the present invention are:

[0029] The decoquinate nano powder of the present invention has a small particle size, is suspended in water, is easy to use, has high bioavailability, a small dosage, and is cost-effective. Therefore, it is particularly suitable for the treatment and prevention of parasites such as coccidiosis, malarial protozoa (avian leukocytozoa), toxoplasma, cryptosporidium, and sarcocystis in livestock and poultry, is easy to use, reduces the cost and the risk of drug resistance, has low drug residue, and ensures the safety of livestock products. DETAILED DESCRIPTION

[0030] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] Example 1

[0032] A method for preparing decoquinate nano powder comprises the following steps:

[0033] (1) Weigh 20 kg of decoquinate and grind it into a superfine grinder to obtain D 50 5μm, D 90 20 μM praziquantel.

[0034] (2) Weigh 0.2 kg of HPMC and Tween 80 10 kg of sodium lauryl sulfate, 0.20 kg of sodium dodecyl sulfate, 1.5 kg of dimethyl silicone oil, 2 kg of poloxamer, add 100 kg of purified water to make a clear solution A for standby use.

[0035] (3) Weigh 0.5 kg of HPMC and 40 kg of maltodextrin, add 100 kg of purified water to prepare a clear and transparent solution B for later use.

[0036] (4) Add the decoquinate obtained in step (1) to the standby solution A obtained in step (2), and grind the mixture thoroughly for 2 hours using a high-pressure homogenizer and a sand mill to obtain a particle size of D 50 100nm, D 90 400nm suspension C.

[0037] (5) The suspension C obtained in step (4) was added to the solution B obtained in step (3), and the mixture was sheared and stirred for 40 minutes. The particle size D of decoquinate was measured. 50 100nm, D 90 400nm, to obtain decoquinate nanosuspension D.

[0038] (6) The decoquinate nanosuspension D obtained in step (5) is transported to a spray drying tower through a pipeline, and the air inlet temperature is set to 100-110°C, the air outlet temperature is 70-80°C, the steam pressure is 0.05, the nozzle pressure is 0.03MPa, and the pressing tank temperature is 70°C. Spraying, powdering, and passing through a 300-mesh sieve are performed to obtain decoquinate nanopowder. It is dissolved in water at a mass ratio of 1:50, and the particle size D of decoquinate is 0.1:1. 50 100nm, D 90 400nm.

[0039] Example 2

[0040] A method for preparing decoquinate nano powder comprises the following steps:

[0041] (1) Weigh 30 kg of decoquinate and grind it into a superfine grinder to obtain D 50 10μm, D 90 30 μM praziquantel.

[0042] (2) Weigh 0.3 kg of HPMC and Tween 80 15 kg, 0.30 kg of sodium lauryl sulfate, 2.0 kg of dimethyl silicone oil, 3 kg of poloxamer, add 100 kg of purified water to make a clear solution A for standby use.

[0043] (3) Weigh 0.75 kg of HPMC and 50 kg of maltodextrin, add 100 kg of purified water to prepare a clear and transparent solution B for later use.

[0044] (4) Add the decoquinate obtained in step (1) to the standby solution A obtained in step (2), and grind the mixture thoroughly for 3 hours using a colloid mill or a sand mill to obtain a particle size of D 50 200nm, D 90 500nm of suspension C.

[0045] (5) The suspension C obtained in step (4) was added to the solution B obtained in step (3), and the mixture was sheared and stirred for 50 minutes. The particle size D of decoquinate was measured. 50 200nm, D 90 500nm, to obtain decoquinate nanosuspension D.

[0046] (6) The decoquinate nanosuspension D obtained in step (5) is transported to a spray drying tower through a pipeline, and the air inlet temperature is set to 110-120°C, the air outlet temperature is set to 60-70°C, the steam pressure is set to 0.07MPa, the nozzle pressure is set to 0.04MPa, and the feed tank temperature is set to 80°C. Spraying, powdering, and passing through a 300-mesh sieve to obtain decoquinate nanopowder. Dissolved in water at a mass ratio of 1:50, the decoquinate particle size D 50 200nm, D 90500nm.

[0047] Example 3

[0048] A method for preparing decoquinate nanopowder, the specific steps are as follows:

[0049] (1) Weigh 40 kg of decoquinate and grind it into a superfine grinder to obtain D 50 15μm, D 90 40 μM decoquinate.

[0050] (2) Weigh 0.4 kg of HPMC and Tween 80 20 kg, 0.40 kg of sodium lauryl sulfate, 2.5 kg of dimethyl silicone oil, 4 kg of poloxamer, add 100 kg of purified water to make a clear solution A for standby use.

[0051] (3) Weigh 1 kg of HPMC and 60 kg of maltodextrin, add 100 kg of purified water to prepare a clear and transparent solution B for later use.

[0052] (4) Add the decoquinate obtained in step (1) to the standby solution A obtained in step (2), and grind the mixture thoroughly for 4 hours using a colloid mill and a high-pressure homogenizer to obtain a particle size of D 50 300nm, D 90 600nm suspension C.

[0053] (5) The suspension C obtained in step (4) was added to the solution B obtained in step (3), and the mixture was sheared and stirred for 60 minutes. The particle size D of decoquinate was measured. 50 300nm, D 90 500nm, to obtain decoquinate nanosuspension D.

[0054] (6) The decoquinate nanosuspension D obtained in step (5) is transported to a spray drying tower through a pipeline, and the air inlet temperature is set to 120-130°C, the air outlet temperature is 80-90°C, the steam pressure is 0.10MPa, the nozzle pressure is 0.05MPa, and the pressing tank temperature is 90°C. Spraying, powdering, and passing through a 300-mesh sieve are performed to obtain decoquinate nanopowder. It is dissolved in water at a mass ratio of 1:50, and the particle size D of decoquinate is 0.10MPa, the steam pressure is 0.10MPa, the nozzle pressure is 0.05MPa, and the pressing tank temperature is 90°C. 50 300nm, D 90 600nm.

[0055] Test example

[0056] (I) Observation on the long-term stability of decoquinate nanopowder

[0057] 1. Strong light irradiation test

[0058] The purpose of the strong light irradiation test is to provide a basis for the packaging and storage conditions of decoquinate nanopowder. The test sample is placed in a comprehensive drug stability test box under an illumination of 4500±500Lx for 10 days. Samples are taken on the 5th and 10th days respectively. The key stability inspection items, such as content, properties, 1:50 water-soluble particle size (D 50 , D 90 ), sedimentation volume ratio, etc.

[0059] The test results of the content, properties, 1:50 water-soluble particle size and sedimentation volume ratio of decoquinate nanopowder in the strong light irradiation test are shown in Table 1. The results of the strong light irradiation test show that under the condition of illumination of 4500±500Lx, when the test was carried out to the 10th day, there was no significant change in content; no significant change in properties; no significant change in particle size; and no significant change in sedimentation volume ratio. The above results show that the quality of decoquinate nanopowder is stable after the strong light irradiation test.

[0060] Table 1 Strong light irradiation test results

[0061]

[0062]

[0063] 2 Accelerated test

[0064] The accelerated test is conducted under extraordinary conditions. Its purpose is to predict the stability of decoquinate nanopowder by accelerating the chemical or physical changes of decoquinate nanopowder, and to provide necessary information for its application for production, transportation and storage. According to the guidance of drug stability test in the Chinese Veterinary Pharmacopoeia, the test sample is placed at 40±2℃ and relative humidity of 75±5% for 6 months. Samples are taken at the end of 1 month, 2 months, 3 months and 6 months respectively, and key stability inspection items such as content, properties, 1:50 water-soluble particle size and sedimentation volume ratio are tested.

[0065] In the accelerated test at a temperature of 40°C and a relative humidity of 75%, the test results of the content, properties, 1:50 water-soluble particle size and sedimentation volume ratio of the decoquinate nanopowder are shown in Table 2. As can be seen from Table 2, the quality of the decoquinate nanopowder after the accelerated test is stable within 6 months.

[0066] Table 2 Accelerated test results

[0067]

[0068]

[0069] In summary, the stability test and the accelerated test show that the decoquinate nanopowder of the present invention has high preparation stability and is a stable veterinary nanopowder that can be produced on a large scale.

[0070] (II) Clinical efficacy of decoquinate nanopowder against coccidioides

[0071] Anti-coccidial effect determination index:

[0072] (1) Relative weight gain rate = average weight gain of the infected medication group / average weight gain of the healthy group × 100%;

[0073] (2) Survival rate = (total number of chickens in the group - number of chickens in each group that died due to coccidia infection) / total number of chickens in the group × 100%;

[0074] (3) Scoring of bloody stools: on the fourth, fifth, sixth, seventh, and eighth days after inoculation of oocysts, refer to the method of Morehouse (1970).

[0075] (4) Lesion value: The cecal lesions were assessed and scored according to the criteria established by Johnsont and Reid (1970);

[0076] Lesion value = average lesion score of each group × 10.

[0077] (5) Oocyst value: calculated based on the OPG value of the cecal contents according to the Kakuta Kiyoshi method.

[0078] (6) Anticoccidial index (ACI) = (relative weight gain rate + survival rate) - (lesion value + oocyst value).

[0079] The criteria for determining drug efficacy are: ACI above 180 is highly effective; 180-160 is moderately effective; 160-120 is low effective; and below 120 is ineffective.

[0080] 1. Clinical effect of decoquinate nanopowder on artificial infection of coccidia

[0081] (1) Test method

[0082] 120 healthy broilers of similar weight at 20 days of age were selected and randomly divided into 6 groups, with 20 chickens in each group being observed in the same conditions. Group 1 was a healthy group without infection and no medication, Group 2 was a pathological group without infection and no medication, and Groups 3 to 6 were Example 1, Example 2, Example 3, and commercially available decoquinate dry suspension. The chicks in Groups 2 to 6 were infected with 2×10 sporulated oocysts of Eimeria tenella. 5 On the day of grouping, 3 to 6 groups of chickens were given Example 1, Example 2, Example 3 and commercially available decoquinate dry suspension with 10 mg / L water every day, and the healthy group was given the same dose of water as a blank control. On the eighth day after infection, the chickens were weighed, killed, and the cecum was taken to observe the cecum lesions and calculate the anticoccidial index (ACI). During the experiment, the diet, morbidity and mortality, and bloody stool of each group of chickens were observed and recorded every day.

[0083] (2) Test results The results are shown in Table 3.

[0084] Table 3 Clinical trial results

[0085] Group No. Bloody stool scoring Survival rate Relative weight gain Lesion value Oocyst value ACI Health Group 0 100 100 0 0 200 Positive control group 4 60 63.91 25.5 40 58.41 Example 1 0 100 96.06 5.65 0 190.41 Example 2 0 100 94.41 6.60 0 187.81 Example 3 0 100 92.16 7.5 0 184.66 Commercially available group 0 100 89.65 8.71 5 170.94

[0086] It can be seen from the above table that the groups of Example 1, Example 2 and Example 3 are highly effective, the commercially available group is moderately effective, and Example 1 is the best, followed by Example 2, and Example 3 is the third. This further illustrates that the smaller the decoquinate nanoparticle size, the more prominent the drug effect.

[0087] 2. Experimental study on the effect of decoquinate nanopowder in treating natural coccidia infection (coccidia outbreak).

[0088] (1) Experimental design

[0089] According to the principle of similar weight, 100 sick chickens with similar weight were selected and randomly divided into 5 groups, each with 20. One group was the positive control group (no drug was given), and the other 4 groups were respectively Example 1, Example 2, Example 3 and commercially available drug administration groups (chickens were allowed to drink Example 1, Example 2, Example 3 and commercially available decoquinate dry suspension with 10 mg / L water every day). In addition, 20 healthy chickens with similar weight were selected as the healthy control group. During the test, the diet, morbidity and mortality, and bloody stool of each group of chickens were observed and recorded every day. On the 8th day after the start of the test, the test chickens were weighed, all killed, dissected, and the cecum was taken to observe the cecal lesions. The oocyst value was converted according to the OPG value of the cecal contents, and the anti-coccidial index (ACI) was calculated to evaluate the efficacy index of each group.

[0090] (2) Test results The results are shown in Table 4.

[0091] Table 4 Clinical trial results

[0092] Group No. Bloody stool scoring Survival rate Relative weight gain Lesion value Oocyst value ACI Health Group 0 100 100 0 0 200 Positive control group 6 75 35.05 40.25 40 25.20 Example 1 0 100 97.56 1.8 0 195.76 Example 2 0 100 95.25 2.5 1 191.75 Example 3 0 100 93.08 3.0 2 188.08 Commercially available group 0 100 86.20 7.5 4 175.70

[0093] It can be seen from the above table that the groups of Example 1, Example 2 and Example 3 are highly effective, the commercially available group is moderately effective, and Example 1 is the best, followed by Example 2, and Example 3 is the third. This further illustrates that the smaller the decoquinate nanoparticle size, the more prominent the drug effect.

[0094] The above implementation examples show that the decoquinate nanopowder of the present invention has the characteristics of good stability, small dosage, high efficacy and good effect, and has high cost performance for preventing and treating coccidia in livestock and poultry. It has a very broad prospect for promotion and application and industrialization in large-scale farms and pastoral areas.

[0095] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A method for preparing decoquinate nanopowder, characterized in that: The following steps are involved: (1) Weigh a certain amount of decoquinate and add it to an ultrafine grinder to obtain D 50 5~15μm, D 90 20-40 μm decoquinate; (2) Weigh a certain amount of HPMC, Tween 80, sodium lauryl sulfate, dimethyl silicate, and poloxamer, add them to purified water to obtain solution A, and set aside; (3) Weigh a certain amount of HPMC and maltodextrin, add them into purified water to obtain solution B, and set aside; (4) Add decoquinate to solution A and grind thoroughly to obtain a particle size D 50 100~300nm、D 90 400-600nm suspension C; (5) Suspension C is added to solution B, sheared and stirred, and the particle size D of decoquinate is detected. 50 100~300nm、D 90 400-600 nm, to obtain decoquinate nanosuspension D; (6) The decoquinate nanosuspension D was spray dried, powdered, and passed through a 300-mesh sieve to obtain decoquinate nanopowder.

2. The method for preparing a decoquinate nanopowder according to claim 1, characterized in that: The mass ratio of decoquinate in step (1) to HPMC, Tween 80, sodium lauryl sulfate, dimethicone, poloxamer and purified water in step (2) is (20-40):(0.2-0.4):(10-20):(0.20-0.40):(1.5-2.5):(2-4):

100.

3. The method for preparing a decoquinate nanopowder according to claim 1, characterized in that: The mass ratio of the decoquinate in step (1) to the HPMC, maltodextrin and purified water in step (3) is (20-40):(0.5-1):(40-60):

100.

4. The method for preparing a decoquinate nanopowder according to claim 1, characterized in that: The grinding equipment in step (4) is selected from a colloid mill, a high-pressure homogenizer, and a sand mill, and the grinding is performed for 2 to 4 hours.

5. The method for preparing decoquinate nanopowder according to claim 1, characterized in that: The shearing and stirring in step (5) is performed at a speed of 2900 r / min for 40 to 60 min.

6. The method for preparing decoquinate nanopowder according to claim 1, characterized in that: The spray drying in step (6) is set with an inlet air temperature of 100-130°C, an outlet air temperature of 60-90°C, a steam pressure of 0.05-0.10MPa, a nozzle pressure of 0.03-0.05MPa, and a pressure tank temperature of 70-90°C.

7. The method for preparing decoquinate nanopowder according to claim 6, characterized in that: The inlet air temperature is 110-120°C, and the outlet air temperature is 70-80°C.

8. A decoquinate nanopowder, characterized in that: Decoquinate nano powder obtained by the preparation method of decoquinate nano powder according to any one of claims 1 to 7.

9. The decoquinate nanopowder according to claim 8, characterized in that: The decoquinate nanopowder is dissolved in water at a mass ratio of 1:

50. The particle size D 50 100~300nm, D 90 400~600nm.

10. An application of decoquinate nanopowder, characterized in that: The invention relates to the use of the decoquinate nano powder as claimed in any one of claims 8 to 9 in drugs for treating coccidiosis, malarial parasites, toxoplasma, cryptosporidium and sarcocystis in livestock and poultry.

Citation Information

Patent Citations

  • Decoquinate nanometer preparation and preparing method and application thereof

    CN104906044A

  • Decoquinate dispersible tablet as well as preparation method and application thereof

    CN106491549A

  • Preparation method of decoquinate dry suspension

    CN111494322A

  • Nanoparticle formulations of decoquinate in the form of solid solution

    WO2020140197A1